Conduit Pharmaceuticals Inc.
NASDAQ
Real-time Data
01:30 PM
Day's Range
0.300052 wk Range
0.3000Key Statistics
Symbol
CDT
Name
Conduit Pharmaceuticals Inc.
Currency
USD
Exchange
NASDAQ
High
0.34999999
Low
0.30000001
Open
‪0.3350‬
Last
‪0.3130‬
Market Cap
1.52M
Pe Ratio
‪421.25‬
Volume
248.70K
Average Volume
381.37K
Dividend Yield
‪0.00%‬
Change
-0.04
Percent Change
-11.83
Timestamp
2026-07-17
Close
0.31299999
Today Range Start
‪0.3000‬
Today Range End
‪0.3500‬
52 Week Range Start
‪0.3000‬
52 Week Range End
‪461.60‬
Type
Stocks
Country
United States
Compliance - CDT - Conduit Pharmaceuticals Inc.
Compliance
Status
NON_COMPLIANT
Report Date
2025-02-17
Business Screen
COMPLIANT
Financial Screen
NON_COMPLIANT
Compliant Revenue
‪97.00%‬
Non Compliant Revenue
‪2.00%‬
Questionable Revenue
‪1.00%‬
Securities To Market Cap Ratio
‪50.00%‬
Debt To Market Cap Ratio
‪90.00%‬
Historical Data - CDT - Conduit Pharmaceuticals Inc.
Historical Data
Market Cap - CDT - Conduit Pharmaceuticals Inc.
Market Cap
2026-07-16
1.72M
2026-07-15
1.70M
2026-07-14
1.70M
2026-07-13
1.74M
2026-07-10
1.85M
2026-07-09
1.99M
2026-07-08
2.14M
2026-07-07
2.13M
2026-07-06
2.20M
2026-07-02
2.40M
Splits - CDT - Conduit Pharmaceuticals Inc.
Splits
2026-03-27
1-for-25 split (25)
Earnings - CDT - Conduit Pharmaceuticals Inc.
Earnings
Balance Sheet - CDT - Conduit Pharmaceuticals Inc.
Balance Sheet
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
 Assets | 5.65M | 4.19M | 7.22M | 5K | 0 |
| Liabilities | 12.82M | 10.98M | 7.68M | 10.09M | 5.94M |
| Shareholders Equity | -7.17M | -6.79M | -457K | -10.08M | -5.94M |
Cash Flow - CDT - Conduit Pharmaceuticals Inc.
Cash Flow
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Activities | - | - | - | - | - |
| Investing Activities | - | - | - | - | - |
| Financing Activities | - | - | - | - | - |
| End Cash Position | 1.50M | 554K | 4.22M | 0 | 0 |
| Income Tax Paid | - | - | - | - | - |
| Interest Paid | 0 | 80K | 124K | 0 | - |
| Free Cash Flow | -17.95M | -9.73M | -7.72M | -2.26M | -2.15M |
Income Statement - CDT - Conduit Pharmaceuticals Inc.
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expense | - | - | - | - | - |
| Operating Income | -36.66M | -15.11M | -5.26M | -3.16M | -3.17M |
| Non-Operating Interest | - | - | - | - | - |
| Other Income Expense | -2.27M | -1.20M | 5.11M | -1.72M | -484K |
| Pre Tax Income | -39.22M | -17.81M | -535K | -4.88M | -3.65M |
| Income Tax | - | - | - | - | - |
| Net Income | -39.22M | -17.81M | -535K | -4.88M | -3.65M |
| EPS Basic | -1.17K | -38.61K | -0.01 | -0.067483 | -0.050498 |
| EPS Diluted | -1.17K | -38.61K | -0.09 | -0.067483 | -0.050498 |
| Basic Shares Outstanding | 33.30K | 461 | 66.97M | 72.41M | 72.41M |
| Diluted Shares Outstanding | 33.30K | 461 | 66.97M | 72.41M | 72.41M |
| Ebit | -38.90M | -16.30M | -113K | -4.88M | -3.17M |
| Ebitda | -36.88M | -15.34M | -5.34M | -3.42M | -2.76M |
| Net Income Continuous Operations | -39.22M | -17.80M | -535K | -4.88M | -3.65M |
| Minority Interests | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - |
Profile - CDT - Conduit Pharmaceuticals Inc.
Profile
Mic Code
XNCM
Sector
Healthcare
Industry
Biotechnology
Employees
4
Conduit Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing clinical-stage assets that address unmet medical needs. The company concentrates on therapeutic programs in autoimmune diseases and idiopathic male infertility, with research centered on conditions such as Hashimoto’s thyroiditis, uveitis, renal transplant rejection, and preterm labor. Its current pipeline includes assets such as AZD1656 and AZD5904, which are being explored for their potential applications across these treatment areas. Conduit Pharmaceuticals works at the intersection of drug development, clinical research, and asset advancement, aiming to support the progression of novel therapies through the development process. The company is headquartered in Naples, Florida.
Profile Details
Type
Common Stock
Ceo
Dr. Andrew Regan
Address
4581 Tamiami Trail North
City
Naples
State
FL
Zip
34103
Country
United States
Phone
646 491 9132
